Skip to search formSkip to main contentSkip to account menu

BMS 232632

Known as: 232632, BMS, BMS-232632, BMS232632 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (2)

AtazanavirAtazanavir sulfate
CGP 73547CGP 75136CGP 75176CGP 75355

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatography-tandem mass spectrometry following automated solid-phase extraction.
2003
2003
Liquid chromatography-tandem mass spectrometric quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human peripheral blood mononuclear cells (PBMC): practical…
Highly Cited
2002
Highly Cited
2002
In Vitro Antiviral Interaction of Lopinavir with Other Protease Inhibitors
ABSTRACT The in vitro inhibition of wild-type human immunodeficiency virus (HIV) by combinations of lopinavir and six other… 
Review
2002
Review
2002
Atazanavir: a novel HIV-1 protease inhibitor
The introduction of HIV-1 protease inhibitors in 1995 ushered in the era of highly active antiretroviral therapy. For the first… 
2001
2001
Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable.
BMS-232632 is a potent human immunodeficiency type 1 (HIV-1) protease inhibitor with a half-life that allows for once-daily… 
2001
2001
BMS-232632 (Novartis/Bristol-Myers Squibb).
BMS-232632, an azapeptide HIV protease inhibitor, is in development by Bristol-Myers Squibb (BMS), under license from Novartis… 
Highly Cited
2000
Highly Cited
2000
In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632
ABSTRACT BMS-232632 is an azapeptide human immunodeficiency virus (HIV) type 1 (HIV-1) protease inhibitor that displays potent… 
2000
2000
A preliminary pharmacokinetic and pharmacodynamic evaluation of the HIV protease inhibitor BMS-232632 in a protease inhibitor-naive HIV+ population
2000
2000
BMS-232632, a new protease inhibitor, is taken once daily.
1999
1999
BMS-232632 : ANTI-HIV HIV-1 PROTEASE INHIBITOR
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)